4-trans-Hydroxycyclohexylamine
Based on 1 Customer Validation
4-trans-Hydroxycyclohexylamine (trans-4-Aminocyclohexan-1-ol) is an intermediate. 4-trans-Hydroxycyclohexylamine is used in the synthesis of the PGK1 inhibitor Compd 25-4. 4-trans-Hydroxycyclohexylamine is used in research on EGFR-positive esophageal squamous cell carcinoma.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity : 99.98%
- CAS No.: 27489-62-9
- 화학식: C6H13NO
- 분자량:115.17
-
보관:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
용액&용해도
- 순도&문서
- References
-
Help & FAQs
Biological Activity
제품 설명
In Vitro
4-trans-Hydroxycyclohexylamine is a synthetic intermediate used for the preparation of Compd 25-4[1].
4-trans-Hydroxycyclohexylamine is used only as a synthetic precursor in the reductive amination step to generate the final compounds 32a-32d and 33a-33d; its independent biological activity is not directly evaluated in HEK293-JumpIn-NET cells or any other biological system[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. .
Chemical Information
-
CAS No. 27489-62-9
-
Appearance Solid
-
분자량 115.17
-
화학식 C6H13NO
-
Color White to yellow
-
SMILES
N[C@H]1CC[C@H](O)CC1
-
Synonyms
trans-4-Aminocyclohexan-1-ol
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
용액&용해도
In Vitro:
DMSO : 200 mg/mL (1736.56 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
순도&문서
-
Data Sheet (269 KB)
-
SDS (477 KB)
- English - EN (477 KB)
- Français - FR (477 KB)
- Deutsch - DE (477 KB)
- Norwegian - NO (477 KB)
- Español - ES (477 KB)
- Swedish - SV (477 KB)
- Italian - IT (477 KB)
- Korean - KR (477 KB)
- Portuguese - PT (477 KB)
-
Handling Instructions (2659 KB)
References
[1]. Ge J, et al. Pharmacological inhibition of PGK1 suppresses EGFR-positive esophageal squamous cell carcinoma by dual targeting of glycolysis and autophagy-dependent EGFR degradation. Cellular oncology (Dordrecht, Netherlands). 2026 Apr 29;49(3):82. [Content Brief]
[2]. Deretic V, et al. Enhancement of lung levels of antibiotics by ambroxol and bromhexine. Expert opinion on drug metabolism & toxicology. 2019 Mar;15(3):213-218. [Content Brief]
[3]. Dilweg MA, et al. Stereochemical optimization of ,2-substituted cycloalkylamines as norepinephrine reuptake inhibitors. RSC medicinal chemistry. 2024 Dec 12;15(12):4068-4079. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 8.6828 mL | 43.4141 mL | 86.8282 mL | 217.0704 mL |
| 5 mM | 1.7366 mL | 8.6828 mL | 17.3656 mL | 43.4141 mL | |
| 10 mM | 0.8683 mL | 4.3414 mL | 8.6828 mL | 21.7070 mL | |
| 15 mM | 0.5789 mL | 2.8943 mL | 5.7885 mL | 14.4714 mL | |
| 20 mM | 0.4341 mL | 2.1707 mL | 4.3414 mL | 10.8535 mL | |
| 25 mM | 0.3473 mL | 1.7366 mL | 3.4731 mL | 8.6828 mL | |
| 30 mM | 0.2894 mL | 1.4471 mL | 2.8943 mL | 7.2357 mL | |
| 40 mM | 0.2171 mL | 1.0854 mL | 2.1707 mL | 5.4268 mL | |
| 50 mM | 0.1737 mL | 0.8683 mL | 1.7366 mL | 4.3414 mL | |
| 60 mM | 0.1447 mL | 0.7236 mL | 1.4471 mL | 3.6178 mL | |
| 80 mM | 0.1085 mL | 0.5427 mL | 1.0854 mL | 2.7134 mL | |
| 100 mM | 0.0868 mL | 0.4341 mL | 0.8683 mL | 2.1707 mL |
4-trans-Hydroxycyclohexylamine Related Classifications
HY-79722 Related Classifications
Powered by Bioz
Keywords
- 4-trans-Hydroxycyclohexylamine
- 27489-62-9
- trans-4-Aminocyclohexan-1-ol
- Drug Intermediate
- EGFR-mediated ERK phosphorylation
- PGK1
- PRAS40 phosphorylation
- lactate production
- xenograft models
- glucose consumption
- EGFR-positive esophageal squamous cell carcinoma cells
- Cyp3A4-derived metabolite
- HEK293-JumpIn-NET cells
- EGFR degradation
- Inhibitor
- inhibitor
- inhibit